secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001654954-24-006396
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics Q1 2024 net loss $3.1M; cash runway into Q3 2024
---------------------------------------------------------------------

- Cash and equivalents $4.7M as of March 31, 2024, down from $7.4M at Dec 31, 2023.
- Net loss of $3.1M for Q1 2024; R&D expenses rose to $1.6M on STAR-1 trial costs.
- STAR-1 Phase 3 acne trial enrollment on track for completion by end of 2024; topline data expected Q1 2025.
- Partnership discussions ongoing for DMT410 topical botulinum toxin; Japanese patent issued for hyperhidrosis.
- Company expects current cash to fund operations only into Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424006396/0001654954-24-006396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424006396/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-006396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer